Objectives. Myositis-specific autoantibodies (MSAs) are increasingly used to delineate distinct subgroups of JDM. The aim of our study was to explore without a priori hypotheses whether MSAs are associated with distinct clinicalpathological changes and severity in a monocentric JDM cohort.
Introduction
JDM is a highly heterogeneous paediatric-onset idiopathic inflammatory myopathy. The classic diagnostic criteria include proximal muscle weakness with an increase in serum muscle enzymes, and distinct skin rashes. Muscle biopsy typically displays inflammation, myofibre and microvascular alterations [1] . Although modern treatment has improved JDM outcome, recent long-term studies still show significant numbers of patients with ongoing disease or damage [2, 3] , indicating the need for reliable biomarkers of poor outcome. Vasculopathy seems to play a central role in the pathogenesis of muscle involvement and also in other severe extra-muscular features of the disease [4, 5] . JDM may also be classified according to the presence of myositis-specific autoantibodies (MSAs), which are associated with various clinical phenotypes [6, 7] , but autoantibody status alone is not sufficient for predicting prognosis. In contrast, muscle pathology overall severity, in combination with MSAs, is useful for predicting outcome in JDM [8] . However, there has been no report of systematic analysis of the association between clinical outcome, distinct autoantibodies and different specific histological features in JDM. The aim of our study was to determine, in a monocentric cohort of JDM patient recruited over 2 years, whether a specific morphological phenotype may be associated with anti-nuclear matrix protein (NXP2/P140) antibodies and clinical features.
Methods

Patients
The Henri Mondor Hospital research ethics committee gave approval for this study (#12-009 at CPP Ile-deFrance IX), and in accordance with current French legislation, written informed consent was obtained from parents or legal representatives of the children for their participation in the research. Patient serum samples and clinical data were obtained through the French referral centre for rare paediatric inflammatory diseases. All of the patients diagnosed from June 2013 to June 2015 with definite JDM were consecutively enrolled [9] . At diagnosis, all patients received MTX and concomitant steroids, in agreement with international protocol [10] . Clinical data were collected at disease onset and during follow-up at 3 months, 6 months and every year until last evaluation (see supplementary data, section Clinical data, available at Rheumatology online). Remission was defined as the presence of Childhood Myositis assessment scale (CMAS) 548, the absence of active skin disease, and a Physician's Global Assessment Score <1 [11] . For each patient, serum was screened in the same laboratory for ANAs, specific DM antibodies including anti-Mi2, antimelanoma differentiation-associated protein 5 (MDA-5), anti-transcription intermediary factor 1g (TIF-1g), antinuclear matrix protein (NXP-2), anti-small-ubiquitin-likemodifier-activating-enzyme, specific myositis antibodies (anti-aminoacyl-transfer RNA synthesase (anti-ARS) including anti Jo1, PL7, PL12, EJ, OJ and anti-signal recognition particle (SRP)), and myositis-associated antibodies (anti-Ro52, Ku, PM-Scl) (see supplementary data, section Autoantibodies screening, available at Rheumatology online).
Myopathological study
For each patient, 7 mm cryostat cross-sections of the deltoid muscle biopsy was processed for histological staining and immunohistochemistry, as previously described [4] . All biopsies were reviewed blindly for clinical and MSA data by two of us (C.G., J.A.), using the validated score tool for muscle biopsy evaluation in patients with JDM [12] . In addition to the minimal battery used to establish these scores [12] , the presence of ischaemic myofibrillary loss (punch-out vacuoles) [13] assessed by haematoxylineosin and myosin heavy-chain (MyHC) immunostaining and supplementary immunohistological markers (MHC2/ HLA-DR/DQ/DP), C5b-9 fraction of complement (membrane attack complex, MAC), VEGF and hypoxia inducible factor (HIF)-1a were also evaluated (see supplementary data, section Myopathological study, available at Rheumatology online).
Statistical analysis
Multiple correspondence analysis (MCA) was performed to describe individuals with reference to a set of categorical histopathological variables. Among them, quantitative variables were dichotomized depending on the median value. Hierarchical clustering on principal components then allowed clustering of patients without a priori hypotheses. The comparisons between identified histopathological subgroups for other variables were performed using the Fisher's exact test for qualitative variables and the MannWhitney U test for quantitative variables. For the longitudinal clinical data (from tests repeated over time, including CMAS, manual muscle testing (MMT), treatment lines and remission rate), linear mixed models were performed regarding the two histopathological clusters identified and MSA status (NXP2+ patient vs NXP2 À patients). Mixed models allowed us to take into account both withinpatient correlation and between-patient variability. All statistical analyses were conducted using R software [14] . The significance level was set at 0.05 and all tests were two-tailed.
Results
Clinical and biological description of the cohort
Clinical and biological characteristics of the patients are listed in supplementary table S1, available at Rheumatology online. A total of 24 patients with JDM (17 females, 7 males) were referred to our reference centre. 39.1% of patients (n = 9/23). Autoantibodies were anti-MDA5 antibodies in two patients, TIF1g in four, no detected antibodies in eight. Patients received one to three lines of treatment in the first 6 months (prednisone, MTX, plasmapheresis/immunoadsorption or rituximab), and 54.5% of patients were still under two or more treatment lines after 2 years. Of the 23 patients, 5 (21.7%), including 2/9 (22%) NXP2+ patients, developed calcinosis during the course of JDM.
Multivariate analysis on histopathological parameters MCA performed on 26 histopathological parameters included in the score tool for JDM muscle biopsies scoring yielded a main dimension (x-axis; dimension 1) taking into account 30, 9% of the information in the dataset. A second dimension (y-axis; dimension 2), taking into account 12, 6% of the information in the dataset, is detailed in supplementary table S2, available at Rheumatology online. According to an R 2 score > 0.6, three myopathological variables were prominently related to the main dimension (dimension 1): total score (TS), vascular domain and visual analogical score. This dimension described a vascular axis and opposed individuals with respect to myopathological severity. In fact, the axis opposed individuals with TS < 20, visual analogical score < 6 or vascular domain = 0/1 to others. Another set of variables impacted significantly, but more weakly (R 2 < 0.6), on the distribution of patients in the main dimension (supplementary Fig. S1 , available at Rheumatology online).
Clustering analysis and classification of the subjects
The 23 patients were then classified using the MCA results. Hierarchical clustering on principal components analysis yielded a hierarchical tree. The optimal final solution consisted of two clusters of patients (n = 11 vs n = 12) and split the factorial map into two, mainly in the horizontal axis (dimension 1) (Fig. 1A) . The two clusters mostly differed in the total muscle biopsy score (100.0% of patients in cluster 1 had a score 5 20, vs 25.0% in cluster 2) and the visual analogic score (100.0% vs 25.0% had a score 56). Thus, the myopathological disease ( Fig. 2 ) was more severe in cluster 1 than in cluster 2. Severe ischaemic features were more prominent in cluster 1 than in cluster 2, as assessed by: high vascular domain score (100% vs 41.7% had a score >1); microinfarcts (100% vs 58.3%); ischaemic punched-out vacuoles (90.9% of patients in cluster 1 had more than a cut-off of 38% of myofibres with punched-out vacuoles in the most injured fascicle, vs 25.0% in cluster 2); and obvious capillary loss (81.8% vs 16.7%). Some other histopathological criteria significantly differed between the two clusters: all JDM cases displayed C5b-9/MAC immunoreactivities, with prominent microvascular MAC deposits (increased MAC scoring in 90.9% vs 33.3%), consistent with the higher level of vascular damage found in cluster 1. Ischaemia biomarkers HIF-1a and VEGF were found abnormally expressed by perifascicular, mostly atrophic, fibres (Fig. 2I and J) . In addition, few perimysial mononuclear cells, likely macrophages, also expressed HIF-1a (Fig. 2I) .
Prognostic characterization of the two histopathological clusters
The two histopathological clusters correspond to two groups of patients clearly differentiated by distinct initial presentation and outcome (supplementary Table S1 , available at Rheumatology online). Indeed, at disease onset, patients in cluster 1: displayed more clinical muscle involvement [lower CMAS (median = 4.5; P = 0.03), lower MMT (median= 44; P = 0.008)]; gastrointestinal involvement at disease onset was a major feature (72.7 vs 8.3%; P = 0.003); active skin lesions (limb subcutaneous oedema: 36.4% vs 16.7%) and calcinosis during the follow-up (36.4% vs 8.3%) also tended to be more frequent, but the difference was not statistically significant. Regarding the clinical longitudinal data (CMAS, MMT, remission rate and treatment lines), mixed linear models showed that more treatment lines were clinically required, notably within the first 6 months (P = 0.030), and cluster 1 patients presented more pronounced muscle weakness (MMT, P = 0.005; CMAS, P = 0.002). Regarding the course of the disease, fewer cluster 1 patients were in remission at 1-year post-diagnosis (trend; P = 0.075) (Fig. 1B and C) . Most importantly, there were significantly more anti-NXP2 antibodiespositive patients in cluster 1 [7/11 (63.6%) vs 2/12 (16.7%); P = 0.036] (Fig. 1A) . The remaining 4/11 patients in cluster 1 presented no tested autoantibodies (3/11) or anti-TIF1 autoantibodies (1/11).
Association between NXP2 autoantibodies and prognosis
Finally, we compared clinical features and outcome of NXP2 + to NXP2 À patients. NXP2-positive subjects were more likely to present severe muscle involvement (MMT, P = 0.014; CMAS, P = 0.003) and required more treatment lines (P = 0.028). Fewer NXP2 + patients were in remission during the follow-up period (P = 0.043) ( Fig. 1D and E) . 
Discussion
In this study we confirmed the heterogeneity of histopathological pattern in JDM, and identified two distinct severity subgroups. Systematic examination of muscle biopsies using consensus scoring was performed blind for results of antibody testing and subjected to multivariate analysis without a priori hypotheses. Patients belonging to cluster 1, with the most severe histological changes (assessed by the vascular domain score, the TS and the visual analogical score), also presented with the most pronounced initial muscle weakness (assessed by CMAS and MMT) and more gastrointestinal involvement. These patients needed more therapeutic escalation, requiring adjunctive immunosuppressive treatments, had lower remission rate and significantly more often had circulating anti-NXP2 antibodies. Similarly, clinical longitudinal data analysis showed that NXP2+ patients had a more severe muscular disease and poorer outcome than NXP2À patients. The present study confirms that perivascular inflammation with muscle capillary dropout is a central feature in the pathogenesis of JDM and is associated with clinical severity. In addition to capillary density, we studied the presence of myofibrillary loss (punch-out vacuoles), a robust marker of muscle ischaemia coextensive with capillary damage in JDM [13] that was more pronounced in cluster 1. We propose that myofibrillary loss should be quoted on a systematic basis, as are other vascular features in JDM (i.e. capillary loss with arteriolar changes, microvascular deposits of MAC and microinfarcts) in order to improve assessment of the vascular score in JDM. Furthermore, as previously described [15] , we observed hypoxia-associated changes in perifascicular areas and adjacent perimysium. Interest in muscle biopsy in JDM has recently revived, and other works have linked vasculopathy and muscle ischaemic features to more severe clinical phenotypes [5, 16, 17] . It has been concluded that muscle biopsy is not only a diagnostic tool; it can also help indicate the prognosis of patients [8] .
Anti-NXP2 autoantibodies, originally called anti-MJ autoantibodies, were first reported in a JDM cohort. They target NXP2 (also known as MORC3), a protein involved in transcriptional regulation [18] . Anti-NXP2 autoantibodies were first regarded as more specifically associated with calcinosis in JDM [7, 19] . In the present cohort, only two out of nine patients with anti-NXP2 autoantibodies had calcinosis, but with the limits of a follow-up not exceeding 2 years. Indeed, the development of calcinosis has been associated with delayed diagnosis, chronic disease course and inadequate treatment, and the median follow-up duration has ranged from 4 years [19] to 7.9 years [7] in previous series. Furthermore, histopathological lesion severity in JDM patients with anti-NXP2 autoantibodies, anti-Tif1g antibodies or without detectable autoantibodies was previously found to be associated with an increased risk of remaining under treatment over time. This was assessed by visual analogical score and TS, without specification on the vascular domain score [8] . Of note, in adults, anti-NXP2 autoantibodies have also been detected in patients and were seldom reported in association with calcinosis and clinical severity [20] .
Although we ensured the homogeneity of the dataset, the monocentric design of our study restricted the number of included patients. A replication cohort or a multicentre study would strengthen our results. Despite its limits, the present study identified ischaemic myopathological features and anti-NXP2 antibodies as complementary biomarkers associated with clinical severity and poor prognosis.
